FindTrial
Sign In

ZOSYN 2.25 for Intravenous Injection, ZOSYN 4.5 for Intravenous Injection and ZOSYN 4.5 for I.V. Infusion Bag (Special drug use-results survey of ZOSYN in malignant tumor except the blood-forming organ malignant tumor patients with febrile neutropenia)

ZOSYN 2.25 for Intravenous Injection, ZOSYN 4.5 for Intravenous Injection and ZOSYN 4.5 for I.V. Infusion Bag (Special drug use-results survey of ZOSYN in malignant tumor except the blood-forming organ malignant tumor patients with febrile neutropenia)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080223166
Enrollment
1000
Registered
2016-04-08
Start date
2016-04-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

febrile neutropenia

Interventions

investigational material(s) Generic name etc : ZOSYN 2.25 for Intravenous Injection, ZOSYN 4.5 for Intravenous Injection INN of investigational material : tazobactam, piperacillin Therapeutic category

Sponsors

Taiho Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Over 15 years-old. The case that have not enrolled in this study. The case that can be given the safety assessment of this agent.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Safety:Adverce event expression situation Efficacy:Clinical response, Bacteriological effect Side effect frequencies calculation Calculation of the clinical response(response rate) and the bacteriological effect(disappearance rate)—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026